1-4 of 4
Kyle Jensen
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase 1/2, Open-Label, Multi-Center Study Assessing the Safety, Tolerability and Preliminary Efficacy of CD123 Natural Killer Cell Engager (NKCE), SAR443579, in Combination with Venetoclax and Azacitidine in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy

Anthony S. Stein, Emma Searle, Sylvain Garciaz, Uma Borate, Kyle Jensen, Asma Kefsi, Marie Bernardo, Yue Yang, Sarah Cooley, Ashish Bajel
Journal: Blood
Blood (2024) 144 (Supplement 1): 2883.3.
https://doi.org/10.1182/blood-2024-205923
Published: 2024
Journal Articles

First-in-Human Study of the CD123 NK Cell Engager SAR443579 in Relapsed or Refractory Acute Myeloid Leukemia, B-Cell Acute Lymphoblastic Leukemia or High Risk-Myelodysplasia: Updated Safety, Efficacy, Pharmacokinetics and Pharmacodynamics

Ashish Bajel, Sylvain Garciaz, Pinkal Desai, Gerwin A Huls, Abhishek Maiti, Mojca Jongen-Lavrencic, Nicolas Boissel, Stephane De Botton, David C. de Leeuw, Shaun Fleming, C. Michel Zwaan, Martha Arellano, David Avigan, Jennifer N. Saultz, Ioannis Mantzaris, Kyle Jensen, Timothy Wagenaar, Gu Mi, Samira Ziti-Ljajic, Dobrin Draganov, Giovanni Abbadessa, Anthony Selwyn Stein
Journal: Blood
Blood (2023) 142 (Supplement 1): 3474.
https://doi.org/10.1182/blood-2023-173162
Published: 2023
Journal Articles

A Phase I, Single-Arm, Open Label, Dose Escalation, Multicenter Study of Off-the-Shelf Natural Killer (NK) Cells (SAR445419) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

Marina Y. Konopleva, Vijaya Raj Bhatt, Ioannis Mantzaris, Abhishek Maiti, Krishna Gundabolu, Kyle Jensen, Jolie Schafer, Gu Mi, Agata Drewniak, Heidi Krenz, Rao Saleem, Giovanni Abbadessa, Naval Daver
Journal: Blood
Blood (2023) 142 (Supplement 1): 5972.
https://doi.org/10.1182/blood-2023-174030
Published: 2023
Journal Articles

An Open-Label, First-in-Human, Dose-Escalation Study of SAR443579 Administered As Single Agent By Intravenous Infusion in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-Cell Acute Lymphoblastic Leukemia (B-ALL) or High-Risk Myelodysplasia (HR-MDS)

Anthony S. Stein, Ashish Bajel, Shaun Fleming, Mojca Jongen-Lavrencic, Sylvain Garciaz, Abhishek Maiti, Nicolas Boissel, Stephane De Botton, Gerwin A. Huls, David C. de Leeuw, David Avigan, Kyle Jensen, Brigitte Demers, Timothy Wagenaar, Gu Mi, Samira Ziti-Ljajic, Dobrin Draganov, Giovanni Abbadessa, Andrew H Wei
Journal: Blood
Blood (2022) 140 (Supplement 1): 7476–7477.
https://doi.org/10.1182/blood-2022-166000
Published: 2022